Document is current
Any future updates will be listed below
-
Authors
Cichon, Joseph https://orcid.org/0000-0003-4318-9707
Joseph, Thomas T. https://orcid.org/0000-0003-1323-3244
Lu, Xinguo
Wasilczuk, Andrzej Z. https://orcid.org/0000-0002-1492-2319
Kelz, Max B. https://orcid.org/0000-0002-2803-6078
Mennerick, Steven J.
Zorumski, Charles F.
Nagele, Peter https://orcid.org/0000-0001-8369-3858
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM151160-01, K08GM139031, GM112596)
BBRF Young Investigator award
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH122379, MH122379)
American Foundation for Prevention of Suicide, Brain & Behavior Research Foundation to P.N
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 4 March 2025
First Online: 3 April 2025
Competing interests
: P.N. is currently receiving or has received funding from NIMH, American Foundation for Prevention of Suicide, and has received reimbursement as advisory board member for Becton-Dickinson unrelated to this work and has previously filed for intellectual property protection related to the use of nitrous oxide in major depression and is the co-founder of NitroTherapeutics, Inc., a company that aims to develop nitrous oxide as treatment for major depression. He has received remuneration from the American Society of Anesthesiologists for serving as editor in the journal Anesthesiology. C.F.Z. serves on the Scientific Advisory Board of Sage Therapeutics and has equity in the company. Sage Therapeutics was not involved in this work. The remaining Authors declare no competing interests.
